
zzso are a continuing source of controversy in clinical trials of zzso zzso zzso zzso The most visible disagreement is about the respective roles of morbidity and mortality as zzso and laboratory zzso as zzso Laboratory zzso have been intensely examined as possible surrogates for clinical zzso but the definition of the usual clinical zzso occurrence or recurrence of an zzso condition or zzso received little critical zzso First disease progression has serious weakness as an zzso and one should consider zzso In this paper, we suggest using zzso schemes to rank patients' zzso histories and then using the ranks as an outcome measure, an extension of the work by zzso et zzso on heart zzso We evaluated six zzso ranking schemes for zzso trials by applying them to 60 participants in zzso zzso and comparing the results to zzso rankings given by five zzso The zzso rankings were in good agreement with each other, and the six zzso schemes were clearly differentiated by their degree of agreement with the zzso zzso The ranking scheme most in zzso with the experts ranked patients first by seriousness of their most serious zzso disease, second by the timing of that disease, and the third by the total number of zzso diseases they zzso Finally, we used this zzso rankings to zzso zzso zzso 

